Tags: Colorectal cancer
Overcoming the Hurdles: Surmounting Acquired Resistance to Anti-EGFR Therapy in Metastatic Colorectal Cancer
Abstract: Colorectal cancer is the third most prevalent cancer type in the United States, with an alarming incidence and mortality rate, especially among individuals younger than […]
Highlights in Colorectal Cancer
Neoadjuvant Chemotherapy Allows Most Patients With Locally Advanced Rectal Cancer to Skip Pelvic Chemoradiation The phase 3 PROSPECT trial found that the addition of neoadjuvant chemotherapy […]
The Use of Immunotherapy in Metastatic Microsatellite-Stable Colorectal Cancer
H&O What percentage of cases of metastatic colorectal cancer (CRC) fall into the microsatellite-stable (MSS) category? CL Approximately 95% to 96% of patients with metastatic CRC […]
Who Is a Candidate for Nonoperative Management of Early-Stage Rectal Cancer?
H&O What is standard treatment for early-stage rectal cancer? CH Surgery is the standard treatment for early-stage rectal cancer. In patients with T1N0 disease, the standard […]
Sequencing Strategies in the Management of Metastatic Colorectal Cancer With HER2 Amplification
H&O How common is HER2 amplification in metastatic colorectal cancer (CRC)? KR HER2 amplification is seen in approximately 2% to 3% of unselected patients with CRC. […]
Optimizing Administration of Third-Line Treatment in Metastatic Colorectal Cancer
Abstract: The past decade has seen substantial improvements in outcomes among patients with metastatic colorectal cancer treated with first and second lines of therapy. An increasing number […]
The Emergence of Targetable Pathways in Colorectal Cancer
Abstract: Colorectal cancer continues to be one of the leading causes of cancer-related morbidity and mortality globally. Despite an overall decreasing incidence of the disease, early-onset […]
How Quality of Life Can Inform Management Decisions in Later-Line Metastatic Colorectal Cancer
Abstract: For many years, the focus of treatment in patients with metastatic colorectal cancer has been to prolong patient survival. Increasing evidence, however, highlights the quality-of-life issues […]
Highlights in Colorectal Cancer From the 2021 American Society of Clinical Oncology Annual Meeting
A Review of Selected Presentations From the 2021 ASCO Annual Meeting • June 4-8, 2021 Final Overall Survival for the Phase III KN177 Study: Pembrolizumab […]
Cases in the Management of Metastatic Colorectal Cancer: Regorafenib as Second-Line Therapy After FOLFOXIRI Plus Bevacizumab in a Patient With a KRAS Mutation
Regorafenib as Second-Line Therapy After FOLFOXIRI Plus Bevacizumab in a Patient With a KRAS Mutation Tanios S. Bekaii-Saab, MD Patient Case A 53-year-old woman presented […]
Considerations in the Management of Younger Patients With Colorectal Cancer
Abstract: The incidence of colorectal cancer in patients ages 18 to 49 years has increased by 51% throughout the past 3 decades. In the United States, recent […]
Cases in the Management of Metastatic Colorectal Cancer: Rechallenge With Chemotherapy After Regorafenib in a Patient With RAS/BRAF Wild-Type Disease
CASE 3 OF A 3-PART SERIES Patient Case The patient is a 50-year-old man who had been diagnosed with left-sided colon cancer 4 years earlier […]
Cases in the Management of Metastatic Colorectal Cancer: Use of Regorafenib as a Bridge to Chemotherapy
Case 2 of a 3-Part Series Patient Case The patient is a 62-year-old man with a long history of metastatic colorectal cancer (mCRC). His primary […]
Transitioning From Second-Line to Third-Line Therapy in Metastatic Colorectal Cancer
Abstract: In the setting of metastatic colorectal cancer, many gains in patient outcomes have been achieved throughout the last 2 decades. A primary driver of these gains […]
Cases in the Management of Metastatic Colorectal Cancer: Sequencing Therapies in a Patient With the BRAF V600E Mutation
Case 1 of a 3-Part Series Sequencing Therapies in a Patient With the BRAF V600E Mutation Tanios S. Bekaii-Saab, MD Patient Case The patient […]
How to Incorporate a Chemo-Free Interval Into the Management of Metastatic Colorectal Cancer
Abstract: Management of metastatic colorectal cancer reflects a continuum of care. The primary treatment goals are to prolong survival while maintaining the best quality of life. The […]
Optimizing the Treatment Sequence From Second-Line to Third-Line Therapy in Patients With Metastatic Colorectal Cancer
Abstract: In clinical trials of metastatic colorectal cancer, progressive disease after second-line therapy is often defined according to Response Evaluation Criteria in Solid Tumors criteria. In the […]
The Mechanism of Action of Regorafenib in Colorectal Cancer: A Guide for the Community Physician
Abstract: In 2012, the US Food and Drug Administration approved the kinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer who have been previously […]
Sequencing Beyond the Second-Line Setting in Metastatic Colorectal Cancer
Abstract: The standard treatment for patients with metastatic colorectal cancer (mCRC) in the first- and second-line setting is generally chemotherapy, which can be augmented with vascular […]
How I Treat Metastatic Colorectal Cancer
Plus Highlights in Colorectal Cancer From the 2018 American Society of Clinical Oncology • June 1-5, 2018 • Chicago, Illinois How I Treat Metastatic Colorectal […]